Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 6/20 | 0.33 |
| ▸ | NPC1 | O15118 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12093314 | 0.76 | NOS3 (0.46) | NCF1SMPD3USP2CYP1A2CYP3A4 | |
| SCHEMBL16053200 | 0.76 | NCF1 (0.41) | NCF1SMPD3USP2CYP1A2CYP3A4 | |
| SCHEMBL21566140 | 0.75 | ADK (0.41) | RAB9ACRHR1SMN1; SMN2 | |
| SCHEMBL7879316 | 0.73 | SMPD3 (0.46) | NCF1SMPD3USP2CYP1A2CYP3A4 | |
| SCHEMBL26389400 | 0.73 | NCF1 (0.42) | NCF1SMPD3USP2CYP1A2CYP3A4 | |
| SCHEMBL12093307 | 0.73 | NCF1 (0.42) | NCF1SMPD3USP2CYP1A2CYP3A4 | |
| SCHEMBL15300995 | 0.72 | NCF1 (0.38) | NCF1SMPD3CYP1A2KMT2AMEN1 | |
| SCHEMBL25332545 | 0.71 | CYP1A2 (0.37) | NCF1CYP1A2CYP3A4MAPK1HSD17B10 | |
| SCHEMBL30469075 | 0.71 | CYP1A2 (0.37) | NCF1CYP1A2CYP3A4MAPK1HSD17B10 | |
| SCHEMBL156190 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676927-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024187049-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-101160304-A | Substituted aryl 1,4-pyrazine derivatives | PFIZER (US) | 2008-04-09 | — | — | CN | disclosed |
| EP-1871763-A1 | SUBSTITUTED ARYL 1.4-PYRAZlNE DERIVATIVES | Pfizer Products Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006114666-A1 | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060211710-A1 | Substituted aryl 1,4-pyrazine derivatives | PFIZER INC | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211710-A1 | Substituted aryl 1,4-pyrazine derivatives | CRHR1, CRHR2, CRH | NCF1 1298/4885EDNRA 232/4885SMPD3 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.